CN102046174A - 针对氨基吡啶的延长的疗法的组合物和方法 - Google Patents

针对氨基吡啶的延长的疗法的组合物和方法 Download PDF

Info

Publication number
CN102046174A
CN102046174A CN201080000861XA CN201080000861A CN102046174A CN 102046174 A CN102046174 A CN 102046174A CN 201080000861X A CN201080000861X A CN 201080000861XA CN 201080000861 A CN201080000861 A CN 201080000861A CN 102046174 A CN102046174 A CN 102046174A
Authority
CN
China
Prior art keywords
aminopyridine
patient
responders
patients
study
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201080000861XA
Other languages
English (en)
Chinese (zh)
Inventor
A·R·布莱特
R·科恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acorda Therapeutics Inc
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42562065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102046174(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of CN102046174A publication Critical patent/CN102046174A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201080000861XA 2009-02-11 2010-02-11 针对氨基吡啶的延长的疗法的组合物和方法 Pending CN102046174A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US15167909P 2009-02-11 2009-02-11
US61/151,679 2009-02-11
US25956309P 2009-11-09 2009-11-09
US61/259,563 2009-11-09
US28587209P 2009-12-11 2009-12-11
US61/285,872 2009-12-11
US28895309P 2009-12-22 2009-12-22
US61/288,953 2009-12-22
US29925910P 2010-01-28 2010-01-28
US61/299,259 2010-01-28
PCT/US2010/023970 WO2010093839A1 (en) 2009-02-11 2010-02-11 Compositions and methods for extended therapy with aminopyridines

Publications (1)

Publication Number Publication Date
CN102046174A true CN102046174A (zh) 2011-05-04

Family

ID=42562065

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201080000861XA Pending CN102046174A (zh) 2009-02-11 2010-02-11 针对氨基吡啶的延长的疗法的组合物和方法
CN2010800008624A Pending CN101896182A (zh) 2009-02-11 2010-02-11 针对氨基吡啶应用的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010800008624A Pending CN101896182A (zh) 2009-02-11 2010-02-11 针对氨基吡啶应用的组合物和方法

Country Status (22)

Country Link
US (3) US20120029035A1 (https=)
JP (1) JP2012517449A (https=)
KR (3) KR20180114250A (https=)
CN (2) CN102046174A (https=)
AR (1) AR075413A1 (https=)
AU (2) AU2010213663A1 (https=)
BR (2) BRPI1000031A2 (https=)
CA (1) CA2751581A1 (https=)
CL (1) CL2011001927A1 (https=)
CO (1) CO6440534A2 (https=)
EA (1) EA022755B1 (https=)
EC (1) ECSP11011311A (https=)
IL (1) IL214500A0 (https=)
MX (1) MX2011008485A (https=)
NI (1) NI201100155A (https=)
NZ (1) NZ595046A (https=)
PE (1) PE20120791A1 (https=)
SG (2) SG173641A1 (https=)
TN (1) TN2011000403A1 (https=)
TW (2) TW201032809A (https=)
UY (2) UY32444A (https=)
WO (2) WO2010093839A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105993016A (zh) * 2014-02-04 2016-10-05 奥普蒂马塔公司 用于预测医疗效果的方法和系统

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
US20150111930A1 (en) * 2013-10-23 2015-04-23 Afgin Pharma, Llc Topical regional neuro-affective therapy
TW201125562A (en) * 2009-09-04 2011-08-01 Acorda Therapeutics Inc Sustained release fampridine treatment in patients with multiple sclerosis
CN102442942A (zh) * 2010-10-08 2012-05-09 天津和美生物技术有限公司 4-氨基吡啶的多晶型物及其制备和应用
CA2825810A1 (en) * 2011-01-28 2012-08-02 Acorda Therapeutics, Inc. Use of 4-aminopyridine to treat cerebral palsy
CA2864340A1 (en) * 2012-02-13 2013-08-22 Acorda Therapeutics, Inc. Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine
WO2014028387A1 (en) * 2012-08-13 2014-02-20 Acorda Therapeutics, Inc. Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine
RU2580837C1 (ru) * 2015-05-05 2016-04-10 Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Московский Физико-Технический Институт (Государственный Университет)" Кристаллогидрат 4-аминопиридина, способ его получения, фармацевтическая композиция и способ лечения и/или профилактики на её основе
US10172842B2 (en) 2015-09-11 2019-01-08 PharmaDax Inc. Sustained release oral dosage form containing dalfampridine
WO2022124946A1 (ru) * 2020-12-10 2022-06-16 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новые полиморфные формы 4-аминопиридина и их фармацевтическое применение
CN112914884B (zh) * 2021-01-19 2022-02-11 重庆火后草科技有限公司 通过稳态时长置信度测量睡眠状态下的体重值的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5370879A (en) * 1990-02-11 1994-12-06 Elan Corporation, Plc Formulations and their use in the treatment of neurological diseases
US6288026B1 (en) * 1999-02-24 2001-09-11 Heinrich Exner Process and composition for treating diseases with an oil-in-water emulsion
US20050228030A1 (en) * 2004-04-09 2005-10-13 Blight Andrew R Method of using sustained release aminopyridine compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5370879A (en) * 1990-02-11 1994-12-06 Elan Corporation, Plc Formulations and their use in the treatment of neurological diseases
US6288026B1 (en) * 1999-02-24 2001-09-11 Heinrich Exner Process and composition for treating diseases with an oil-in-water emulsion
US20050228030A1 (en) * 2004-04-09 2005-10-13 Blight Andrew R Method of using sustained release aminopyridine compositions

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
《Annals of Neurology》 19870131 D. Stefoski, et al. "4-Armnopyridme Improves Clinical Signs in Multiple Sclerosis" 第71-77页 1-16 第21卷, 第1期 *
《Annals of Neurology》 19900228 Floyd A. Davis,et al. "Orally Administered 4-hnopyridme Improves Clinical Signs in Multiple Sclerosis" 第186-192页 1-16 第27卷, 第2期 *
《中华妇产科杂志》 20061130 瓮占平 等 "42氨基吡啶对卵巢上皮性癌细胞增殖的影响" 第762-765页 1-16 第41卷, 第11期 *
D. STEFOSKI, ET AL.: ""4-Armnopyridme Improves Clinical Signs in Multiple Sclerosis"", 《ANNALS OF NEUROLOGY》, vol. 21, no. 1, 31 January 1987 (1987-01-31), pages 71 - 77 *
FLOYD A. DAVIS,ET AL.: ""Orally Administered 4-hnopyridme Improves Clinical Signs in Multiple Sclerosis"", 《ANNALS OF NEUROLOGY》, vol. 27, no. 2, 28 February 1990 (1990-02-28), pages 186 - 192, XP055260954, DOI: doi:10.1002/ana.410270215 *
瓮占平 等: ""42氨基吡啶对卵巢上皮性癌细胞增殖的影响"", 《中华妇产科杂志》, vol. 41, no. 11, 30 November 2006 (2006-11-30), pages 762 - 765 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105993016A (zh) * 2014-02-04 2016-10-05 奥普蒂马塔公司 用于预测医疗效果的方法和系统
CN105993016B (zh) * 2014-02-04 2020-01-10 奥普蒂马塔公司 用于为具有特定疾病的个体规划医疗的计算机化系统

Also Published As

Publication number Publication date
JP2012517449A (ja) 2012-08-02
AU2016219650C1 (en) 2018-08-23
CO6440534A2 (es) 2012-05-15
CA2751581A1 (en) 2010-08-19
KR20170034452A (ko) 2017-03-28
AU2016219650A1 (en) 2016-09-15
WO2010093839A1 (en) 2010-08-19
SG10201609184PA (en) 2016-12-29
AU2016219650B2 (en) 2018-05-10
NI201100155A (es) 2012-02-16
US20120029035A1 (en) 2012-02-02
EA201171043A1 (ru) 2012-02-28
ECSP11011311A (es) 2011-10-31
WO2010093838A1 (en) 2010-08-19
EA022755B1 (ru) 2016-02-29
IL214500A0 (en) 2011-09-27
TW201034665A (en) 2010-10-01
SG173641A1 (en) 2011-09-29
UY32445A (es) 2010-09-30
AU2010213663A1 (en) 2011-09-29
CL2011001927A1 (es) 2012-07-20
BRPI1000031A2 (pt) 2018-02-14
UY32444A (es) 2010-09-30
NZ595046A (en) 2013-10-25
AR075413A1 (es) 2011-03-30
CN101896182A (zh) 2010-11-24
TN2011000403A1 (en) 2013-03-27
KR20120000560A (ko) 2012-01-02
MX2011008485A (es) 2011-11-04
US20170319562A1 (en) 2017-11-09
US20150313886A1 (en) 2015-11-05
BRPI1000030A2 (pt) 2018-02-14
KR20180114250A (ko) 2018-10-17
PE20120791A1 (es) 2012-07-08
TW201032809A (en) 2010-09-16

Similar Documents

Publication Publication Date Title
CN102046174A (zh) 针对氨基吡啶的延长的疗法的组合物和方法
US9925173B2 (en) Methods of using sustained release aminopyridine compositions
US20220016095A1 (en) Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
CN101827522A (zh) 持续释放氨基吡啶组合物的使用方法
TW201125562A (en) Sustained release fampridine treatment in patients with multiple sclerosis
US20240041850A1 (en) Methods of Using Sustained Release Aminopyridine Compositions
HK1157591A (en) Compositions and methods for extended therapy with aminopyridines
AU2016216601B2 (en) Methods of using sustained release aminopyridine compositions
JP2018127497A (ja) アミノピリジンを使用した、ある種の卒中に関連した感覚運動障害を治療するための方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1157591

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110504

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1157591

Country of ref document: HK